Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) Net Margin (2016 - 2025)

Immucell's Net Margin history spans 16 years, with the latest figure at 37.36% for Q4 2025.

  • For Q4 2025, Net Margin fell 4400.0% year-over-year to 37.36%; the TTM value through Dec 2025 reached 3.76%, up 423.0%, while the annual FY2025 figure was 3.76%, 438.0% up from the prior year.
  • Net Margin reached 37.36% in Q4 2025 per ICCC's latest filing, down from 2.54% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 17.94% in Q1 2025 to a low of 67.17% in Q1 2023.
  • Average Net Margin over 5 years is 12.62%, with a median of 10.74% recorded in 2021.
  • Peak YoY movement for Net Margin: crashed -7943bps in 2023, then surged 6114bps in 2024.
  • A 5-year view of Net Margin shows it stood at 1.36% in 2021, then tumbled by -3232bps to 42.65% in 2022, then skyrocketed by 59bps to 17.42% in 2023, then surged by 138bps to 6.64% in 2024, then crashed by -663bps to 37.36% in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Net Margin are 37.36% (Q4 2025), 2.54% (Q3 2025), and 7.79% (Q2 2025).